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Summary
Background The benefits of reducing blood pressure on the
risks of major cardiovascular disease are well established,
but uncertainty remains about the comparative effects of
different blood-pressure-lowering regimens. We aimed to
estimate effects of strategies based on different drug
classes (angiotensin-converting-enzyme [ACE] inhibitors,
calcium antagonists, angiotensin-receptor blockers [ARBs],
and diuretics or  blockers) or those targeting different blood
pressure goals, on the risks of major cardiovascular events
and death. 
Methods We did seven sets of prospectively-designed
overviews with data from 29 randomised trials (n=162 341).
The trial eligibility criteria, primary outcomes, and main
hypotheses were specified before the result of any
contributing trial was known. 
Findings In placebo-controlled trials the relative risks of total
major cardiovascular events were reduced by regimens
based on ACE inhibitors (22%; 95% CI 17–27) or calcium
antagonists (18%; 5–29). Greater risk reductions were
produced by regimens that targeted lower blood pressure
goals (15%; 5–24). ARB-based regimens reduced the risks of
total major cardiovascular events (10%; 4–17) compared with
control regimens. There were no significant differences in
total major cardiovascular events between regimens based
on ACE inhibitors, calcium antagonists, or diuretics or 
 blockers, although ACE-inhibitor-based regimens reduced
blood pressure less. There was evidence of some differences
between active regimens in their effects on cause-specific
outcomes. For every outcome other than heart failure, the
difference between randomised groups in achieved blood
pressure reduction was directly related to the observed
difference in risk.
Interpretation Treatment with any commonly-used regimen
reduces the risk of total major cardiovascular events, and
larger reductions in blood pressure produce larger reductions
in risk.
Lancet 2003; 362: 1527–35
Introduction
Cardiovascular diseases are the leading cause of death
worldwide;1 about two-thirds of the cerebrovascular
disease burden and half the ischaemic heart disease
burden are attributable to non-optimum blood pressure.2
The beneficial effects of blood-pressure-lowering
treatments on the risks of major cardiovascular events are
well established,3–8 but little is known about the
comparative effects of regimens based on different drug
classes or regimens targeting different blood pressure
goals.4,9,10 Reliable information about the size of benefits
achieved with different blood-pressure-lowering regimens
is of great importance—if one regimen proved even
slightly better than another, then preferential use of the
more effective regimen might prevent tens of thousands of
major cardiovascular events every year.
The uncertainty about the comparative effects of
different regimens in part reflects the limited statistical
power of most individual studies to identify plausible
differences in the size of treatment effects, and differences
between studies in selection of patients, choice of
outcome definitions, and achieved blood pressure
reductions. The Blood Pressure Lowering Treatment
Trialists’ Collaboration was established to undertake a
series of prospectively-designed systematic overviews to
investigate the effects of different blood-pressure-lowering
regimens on mortality and major cardiovascular events.11
Results of the first round of analyses were reported in
2000.4 The first meta-analyses showed benefits of blood-
pressure-lowering regimens based on angiotensin-
converting-enzyme (ACE) inhibitors and those based on
calcium antagonists, compared with placebo, but did not
provide definitive evidence about comparative effects of
regimens based on different drug classes and those
targeting different blood pressure goals. In these analyses
we aimed to resolve some of these issues. 
Methods
The methods used by the Blood Pressure Lowering
Treatment Trialists’ Collaboration have been reported
previously,4,11 and only the main components are
summarised here. Trial eligibility criteria, blood pressure
lowering regimens to be compared, and primary outcomes
were all prespecified.11
Trial eligibility 
Inclusion criteria were: 1) random allocation of patients 
to either a blood-pressure-lowering drug or placebo; 2)
random allocation of patients to different blood pressure
goals; or 3) random allocation of patients to regimens
based on different classes of blood-pressure-lowering drug.
Trials were also required to have a planned minimum of
1000 patient-years’ follow-up in each randomised group,
and their main results should not have been reported
before the overview protocol was finalised in July, 1995. In
this and the previous round of analyses,4 overviews were
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done if more than one trial were eligible for any
comparison. Trials that included patients who were
selected mainly on the basis of high blood pressure,
diabetes mellitus, coronary heart disease, peripheral
vascular disease, cerebrovascular disease, or renal disease,
were eligible for inclusion. Investigations of patients who
were selected mainly on the basis of other disorders, such
as acute myocardial infarction or heart failure, were not
included since most of these trials were part of other meta-
analyses. For inclusion in our analyses, follow-up had to be
complete and outcome data available by June, 2003.
Comparisons and outcomes 
For these analyses, we did separate overviews of trials
of: 1) ACE-inhibitor-based regimens versus placebo; 2)
calcium-antagonist-based regimens versus placebo; 3)
regimens targeting different blood pressure goals; 4)
angiotensin-receptor blockers (ARB) regimens versus
control regimens; 5) regimens based on ACE inhibitors
versus regimens based on diuretics or  blockers; 6)
calcium-antagonist-based regimens versus regimens based
on diuretics or  blockers; and 7) ACE-inhibitor-based
regimens versus calcium-antagonist-based regimens. ARB
comparisons differed somewhat from other treatment
comparisons and were therefore presented separately. One
trial12 was a placebo-controlled study in which active
treatment was initiated in a large proportion of the placebo
group early in the study (starting with diuretic-based
regimens but with the addition of agents other than ACE
inhibitors and ARBs, as required). Two trials13,14 used a
placebo control while simultaneously attempting to
achieve blood pressure reductions in both randomised
groups (using blood-pressure-lowering agents other than
ACE-inhibitors and the specific trial intervention
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Treatment comparison n Trial design Entry criteria* Follow-up 
(years)
Active treatment vs placebo
ACE inhibitor vs placebo
HOPE26 Ramipril vs placebo 9297 DB CHD, CVD, or DM+RF 4.5
PART219 Ramipril  vs placebo 617 DB CHD or CVD 4·7
PROGRESS21 Perindopril (+/- indapamide) vs placebo(s) 6105 DB Cerebrovascular disease 3·9
QUIET27 Quinapril vs placebo 1750 DB CHD 2·3
SCAT22 Enalapril vs placebo 460 DB CHD 4·0
Calcium antagonist vs placebo
IDNT13 Amlodipine vs placebo 1136 DB HBP+DM+nephropathy 2·6
NICOLE28 Nisoldipine vs placebo 826 DB CHD 3·0
PREVENT20 Amlodipine vs placebo 825 DB CHD 3·0
SYST-EUR23 Nitrendipine vs placebo 4695 DB HBP, 60 years 2·6
More intensive vs less intensive regimens
AASK29 MAP 92 vs 102–107 mm Hg 1094 Open HBP+nephropathy, Afr 3·8
ABCD (H)30 DBP 75 vs 90 mm Hg 470 Open HBP+DM 5·3
ABCD (N)31 DBP 10 below baseline vs 80–89 mm Hg 480 Open DM 5·3
HOT‡17 DBP 80 vs 85 or 90 mm Hg 18790 Open† HBP 3·8
UKPDS-HDS24 DBP <85 vs <105 mm Hg 1148 Open HBP+DM 8·4
ARBs vs control regimens
IDNT13 Irbesartan vs placebo§ 1148 DB HBP+DM +nephropathy 2·6
RENAAL14 Losartan vs placebo§ 1513 DB DM +nephropathy 3·4
SCOPE12 Candesartan vs placebo§ 4937 DB HBP, 70–89 years 4·5
LIFE15 Losartan vs atenolol 9193 DB HBP +CVD RF 4·8
Different drug classes
ACE inhibitor vs diuretic or  blocker29
AASK29 Ramipril vs metoprolol 877 DB HBP+nephropathy, Afr 4·1
ALLHAT32 Lisinopril vs chlorthalidone 24328 DB HBP + RF 4·9
ANBP233 Enalapril vs hydrochlorothiazide 6083 Open† HBP, 65–84 years 4·1
CAPPP34 Captopril vs  blocker or diuretic 10985 Open† HBP 6·1
STOP-235 Enalapril or lisinopril vs atenolol or metoprolol or 4418 Open† HBP, 70–84 years 5·0
pindolol or hydrochlorothiazide+amiloride
UKPDS-HDS44 Captopril vs atenolol 758 DB HBP+DM 8·4
Calcium antagonist vs diuretic or  blocker
AASK29 Amlodipine vs metoprolol 658 DB HBP+nephropathy, Afr 3·0
ALLHAT32 Amlodipine vs chlorthalidone 24321 DB HBP+ RF 4·9
CONVINCE36 COER-verapamil vs hydrochlorothiazide or atenolol 16476 DB HBP+ RF 3·0
ELSA37 Lacidipine vs atenolol 2334 DB HBP 4·0
INSIGHT38 Nifedipine GITS vs hydrochlorothiazide+amiloride 6321 DB HBP + RF 4·0
NICS-EH18 Nicardipine vs trichlormethiazide 429 DB HBP, 60 years 5·0
NORDIL39 Diltiazem vs  blocker or diuretic 10881 Open† HBP 5·0
SHELL40 Lacidipine vs chlorthalidone 1882 Open HBP, 60 years 3·6
STOP-235 Felodipine or isradipine vs atenolol or metoprolol 4409 Open† HBP, 70–84 years 5·0
or pindolol or hydrochlorothiazide+amiloride
VHAS25 Verapamil vs chlorthalidone 1414 Open HBP 2·0
ACE inhibitor vs calcium antagonist
AASK29 Ramipril vs amlodipine 653 DB HBP+nephropathy, Afr 3·0
ABCD (H)30 Enalapril vs nisoldipine 470 DB HBP+DM 5·3
ABCD (N)31 Enalapril vs nisoldipine 480 DB DM 5·3
ALLHAT32 Lisinopril vs amlodopine 18113 DB HBP+CVD RF 4·9
JMIC-B41 ACE inhibitor vs nifedipine 1650 Open† HBP+CHD 3·0
STOP-235 Enalapril or lisinopril vs felodipine or isradipine 4401 Open† HBP, 70–84 years 5·0
Afr=African American. CHD=coronary heart disease. COER=controlled onset, extended release. CVD=cardiovascular disease. DB=double-blind. DBP=diastolic blood
pressure. DM=diabetes mellitus. GITS=gastrointestinal transport system. HBP=high blood pressure. MAP=mean arterial pressure. RF=other CVD risk factor.
*Definitions of HBP and nephropathy varied between studies. †PROBE (Prospective, Randomised, Open with Blinded Endpoint evaluation) design trials. ‡HOT trial data
analysed as most intensively treated group vs others. §These placebo-controlled trials either had similar blood pressure goals in each randomised group or introduced
active treatment into the placebo group for another reason for a large proportion of participants before the completion of follow-up. 
Table 1: Characteristics of included trials
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treatments). One trial15 was designed as a head-to-head
comparison between active agents. Since all these included
control treatment with agents other than ARBs, we
analysed them as one group. No overviews of regimens
based on -adrenergic receptor blockers were undertaken
because only one trial was eligible.16 For every comparison,
we tested the null hypothesis of no difference between
groups for all six predefined outcomes:4,11 stroke, coronary
heart disease, heart failure, major cardiovascular events (ie,
stroke, coronary heart disease, heart failure, or
cardiovascular death), death from any cardiovascular
cause, and total mortality. For our analyses, the definition
of heart failure included only those events that caused
death or led to admission to hospital.
Data collection and statistical analyses
For every trial, information about baseline characteristics,
blood pressure during follow-up, and outcome events was
obtained from individual participant datasets17–25 or from
tabulated data12–15,26–41 provided by collaborating
investigators. Data were checked for completeness and
balance between randomised groups, and were reviewed
for accuracy on at least two occasions. In several
instances,17–19,22,23,38 data included in the first round of
overviews4 have been updated on the basis of new
information. Mean levels of baseline characteristics and
mean differences in follow-up blood pressure between
randomised comparisons were calculated for groups of
trials with estimates from every individual study weighted
by the number of individuals in the study. Effects of
randomised treatments were analysed with the metan
routine (STATA Release, version 6.0). Relative risks and
95% CIs for every outcome were calculated separately for
every trial, with grouped data, in intention-to-treat
analyses. Overall estimates of effect were calculated with a
fixed-effects model, in which the log relative risk for every
trial was weighted by the reciprocal of the variance of the
log relative risk.42 The assumption of homogeneity
between the treatment effects in different trials was tested
with the 2 Q statistic. If the assumption of homogeneity
was rejected (p<0·10),43 additional analyses were done
with a random effects model.43 Participants could
contribute only one event to the calculation for each
outcome, but could contribute one event to each of the
separate analyses of different outcomes. Associations
between the size of blood pressure reductions and the
observed differences in risk between randomised
comparisons were estimated by plotting pooled relative
risk estimates (and 95% CIs) for every comparison and
outcome against the corresponding mean blood pressure
differences weighted by the number of individuals in each
treatment group. Since the estimates are not independent,
no formal test of association was done.
Role of the funding source
These overviews were designed and reported by a
consensus of members of the Blood Pressure Lowering
Treatment Trialists’ Collaboration. The National Health
and Medical Research Council of Australia funded the
central coordination, analysis, and report writing at The
George Institute for International Health in Sydney,
Australia. Meetings of collaborators in this meta-analysis
were funded by several pharmaceutical companies.
Sponsor representatives were able to attend these meetings
but did not contribute to study design, analysis or
interpretation of results, writing the report, nor did they
influence the decision to submit the report for publication.
Results
Trials and patients
Table 1 shows characteristics of the 29 trials12–15,17–41,44
(162 341 participants) that were included. Nine trials
(25 711 participants, 3548 major vascular events)
provided data from comparisons of an ACE-inhibitor-
based or a calcium-antagonist-based regimen versus
placebo, and five (21982 participants, 1191 major
vascular events) provided data from comparisons of
regimens targeting different blood pressure goals. Four
trials (16791 participants, 2478 major vascular events)
provided data from comparisons of blood-pressure-
lowering regimens based on ARBs versus control
regimens. 16 trials that included 101228 participants and
recorded 10131 major vascular events provided data from
comparisons between active regimens based on ACE
inhibitors, calcium-antagonists, or diuretics or  blockers. 
The mean duration of follow-up ranged from 2·0 to
8·4 years, representing more than 700 000 patient-years.
The overall mean age of trial participants was 65 years,
52% were men (table 2), and most were selected on the
basis of having pre-existing cardiovascular disease or more
than one cardiovascular risk factor at baseline.
Participants’ mean baseline blood pressure was
159/92 mm Hg, with mean values in the contributing trials
ranging between 123 and 194 mm Hg systolic and 74 and
106 mm Hg diastolic. Table 2 shows composite mean
blood pressures for different randomised comparisons
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Treatment comparison Age Men SBP/DBP at Participants remaining on randomised treatment†
(mean, years) entry (mean, mm Hg) or achieving blood pressure goal‡
1st-listed 2nd listed
Active treatment vs placebo§
ACEI vs placebo19,21,22,26,27 64 74% 140/81 73% 75%
CA vs placebo13,20,23,28 66 48% 148/75 74% 69%
More intensive vs less intensive 
regimens24,29–31 61 54% 167/103 56% 80%
ARBs vs controls12–14,41
70 46% 169/93 65% 58%
Different drug classes
ACEI vs diuretic or  blocker24,29,32–35 65 51% 157/90 63% 72%
CA vs diuretic or  blocker18,29,29,32,35–40 66 48% 159/92 75% 75%
ACEI vs CA29–32,35,41 68 51% 154/87 63% 71%
ACEI=ACE inhibitor. CA=calcium antagonist. DBP=diastolic blood pressure. SBP=systolic blood pressure. *For mean age, proportion of men, and mean SBP/DBP at
entry, overall mean values were calculated by weighting the values for every contributing trial by the number of individuals in that trial. For the proportion remaining on
randomised treatment or achieving blood pressure goal, overall mean values for every treatment group were calculated by weighting the values for each group in every
contributing trial by the number of individuals in that group. †Proportion remaining on randomised treatment reported for all placebo-controlled studies and for studies
comparing different active treatments. ‡Proportion achieving blood pressure goal reported for studies comparing more intensive with less intensive blood-pressure
lowering regimens. §Data for adherence were not available for two trials; SCAT and  IDNT.
Table 2: Characteristics of trial participants and adherence to randomised treatment during follow-up*
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trial. High blood pressure was the main inclusion criterion
in 11 trials, but not in the remaining 18 (table 1).
Full information about the adherence of study
participants to randomised treatments (table 2) was
available from all but two trials.13,27 Overall, for most
comparisons between a half and three-quarters of study
participants remained on their randomly assigned study
treatment until the end of follow-up. The proportion of
participants achieving their target blood pressure in the
groups assigned to more intensive blood-pressure
lowering was a little over a half.
All but two small trials13,29 provided information about
mean follow-up blood pressure differences between
randomised groups. In the placebo-controlled trials 
of ACE-inhibitor-based or calcium-antagonist-based
regimens, the weighted average blood pressure levels in
treatment groups during follow-up were 5·4/2·3 mm Hg,
and 8·4/4·2 mm Hg lower, respectively, than in placebo
groups (figure 1). In trials comparing regimens targeting
different blood pressure goals, blood pressure was a mean
of 4·2/3·5 mm Hg lower in groups assigned lower rather
than higher targets. Follow-up blood pressure in groups
assigned an ARB-based regimen were 2·1/0·9 mm Hg
lower than in those assigned control regimens (figure 2).
In trials comparing treatment regimens, follow-up blood
pressure in groups assigned ACE-inhibitor-based
regimens were 1·9/0·2 mm Hg higher than in those
assigned diuretic-based or -blocker-based regimens, and
0·6/0·9 mm Hg higher than in those assigned calcium
antagonists (figure 3). Follow-up blood pressure in groups
assigned calcium-antagonist-based regimens were 0·8/
–0·2 mm Hg higher than in those assigned to regimens
based on diuretics or  blockers. These differences in
blood pressure should be taken into account in
interpretation of our results for mortality and morbidity.
Most trials provided complete information about all six
prespecified primary outcomes according to predefined
criteria. However, one trial29 did not have information for
any cause-specific outcomes, three12,27,28 had no heart
failure data, and five had no information about heart
failure as defined.23,34,35,38,39 One trial28 had no information
about total major cardiovascular events or cardiovascular
death. Data for coronary heart disease from five
trials13,14,22,28,36 did not include sudden death.
Further detailed information about the trials and
analyses is available at http://www.iih.org/bplttc.
Stroke
ACE-inhibitor-based and calcium-antagonist-based
regimens reduced the risk of stroke compared with placebo
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Stroke
ACEI vs placebo19,21,22,26,27
CA vs placebo13,20,23,28
More vs less17,24,30,31
5
4
4
–5/–2
–8/–4
–4/–3
0·72 (0·64–0·81) 0·33
0·62 (0·47–0·82) 0·90
0·77 (0·63–0·95) 0·15
473/9111
76/3794
140/7494
660/9118
119/3688
261/13 394
Coronary heart disease
ACEI vs placebo19,21,22,26,27
CA vs placebo13,20,23,28
More vs less17,24,30,31
5
4
4
–5/–2
–8/–4
–4/–3     
0·80 (0·73–0·88) 0·91
0·78 (0·62–0·99) 0·34
0·95 (0·81–1·11) 0·26
667/9111
125/3794
274/7494
834/9118
156/3688
348/13 394
Heart failure
ACEI vs placebo19,21,22,26,27
CA vs placebo13,20,23,28
More vs less30,31,35,43
5
3
4
–5/–2
–8/–4
–4/–3
0·82 (0·69–0·98) 0·60
1·21 (0·93–1·58) 0·17
0·84 (0·59–1·18) 0·11
219/8233
104/3382
54/7494
269/8246
88/3274
72/13 394
Major cardiovascular events
ACEI vs placebo19,21,22,26,27
CA vs placebo13,20,23,28
More vs less17,24,30,31
5
3
4
–5/–2
–8/–4
–4/–3
0·78 (0·73–0·83) 0·42
0·82 (0·71–0·95) 0·54
0·85 (0·76–0·95) 0·27
1283/9111
280/3382
482/8034
1648/9118
337/3274
719/13 948
Cardiovascular death
ACEI vs placebo19,21,22,26,27
CA vs placebo13,20,23,28
More vs less17,24,29–31
5
4
5
–5/–2
–8/–4
–4/–3
0·80 (0·71–0·89) 0·29
0·78 (0·61–1·00) 0·43
0·93 (0·77–1·11) 0·15
488/9111
107/3382
209/8034
614/9118
135/3274
271/13 948
Total mortality
ACEI vs placebo19,21,22,26,27
CA vs placebo13,20,23,28
More vs less17,24,29–31
5
4
5
–5/–2
–8/–4
–4/–3
0·5 1·0
Relative risk
Favours 1st listed Favours 2nd listed
2·0
0·88 (0·81–0·96) 0·54
0·89 (0·75–1·05) 0·99
0·96 (0·84–1·09) 0·09
839/9111
239/3794
404/8034
951/9118
263/3688
549/13 948
Trials Events/participants
1st listed  2nd listed  
Difference in BP*
(Mean, mm Hg)
Relative risk
(95% Cl)
p
Figure 1: ACE inhibitors and calcium antagonists compared with placebo, and more and less intensive blood-pressure-lowering regimens 
ACEI=ACE inhibitor. CA=calcium antagonist. More=more intensive blood-pressure-lowering regimen. Less=less intensive regimen. p values are derived from
2 test for homogeneity. *Overall mean blood pressure difference (systolic/diastolic) during follow-up in the actively treated group compared with the control
group, calculated by weighting the difference observed in each contributing trial by the number of individuals in the trial. Negative values indicate lower
mean follow-up blood pressure in 1st listed groups (ACE, CA, and more) than in 2nd listed groups (placebo and less).
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(28% [95% CI 19–36]; and 38% [18–53], respectively)
(figure 1). Greater risk reductions were seen with regimens
targeting lower blood pressure goals (23% [5–37]) and the
risk of stroke was reduced with ARB-based regimens
compared with control regimens (21% [10–31]; figure 2).
In comparisons of regimens based on different drug
classes, there were some differences in stroke risk, but
these were of borderline significance (figure 3). There was
a trend towards a greater risk reduction with regimens
based on diuretics or  blockers compared with regimens
based on ACE inhibitors (9% [0–18]), and trends towards
greater reductions with regimens based on calcium
antagonists compared with those based on diuretics or
 blockers (7% [–1 to 14]) or with those based on ACE
inhibitors (12% [1–25]). 
Coronary heart disease
ACE-inhibitor-based regimens reduced the risk of coronary
heart disease (20% [12–27]) compared with placebo (figure
1). There was weaker evidence of a reduction in risk with
calcium-antagonist-based regimens (22% [1–38]). For
regimens targeting lower blood pressure goals, there was no
clear evidence of benefit (5% [–11 to 19]). There was also
no clear difference between ARB-based regimens and
control regimens (4% [–9 to 15]) (figure 2). There was no
significant difference between regimens based on ACE
inhibitors, calcium antagonists, or diuretics or  blockers,
with narrow CIs for the estimate of effect for each
comparison (figure 3). There was significant heterogeneity
among trials that were included in the comparison of ACE-
inhibitor-based and calcium-antagonist-based regimens
(p=0·01). Recalculation of the estimate and its 95% CIs
with a random effects model made little difference (17%
[–5 to 32]). 
Heart failure
For heart failure that caused death or admission to
hospital, there was a beneficial effect from ACE inhibitor-
based regimens compared with placebo (18% [2–31];
figure 1). There was no clear effect of calcium-antagonist-
based regimens (21% [–42 to 7]) or regimens targeting
lower blood pressure goals (16% [–18 to 41]), although
the CIs were wide for both. Compared with control
regimens, ARB-based treatment reduced the risk of heart
failure (16% [3–28]; figure 2). Effects of regimens based
on ACE inhibitors did not differ significantly from effects
of those based on diuretics or  blockers (7% [–4 to 19];
figure 3). However, compared with regimens based on
calcium antagonists, those based on diuretics or
 blockers (33% [21–47]) and on ACE inhibitors (18%
[8–27]) produced greater reductions in risk. 
Major cardiovascular events
Comparisons of regimens based on ACE inhibitors and
calcium-antagonists with placebo both indicated
significant reductions in the composite of all major
cardiovascular events with active treatment (22%
[17–27]; and 18% [5–29], respectively; figure 1). The risk
of this outcome was also reduced with regimens targeting
lower blood pressure goals (15% [5–24]). ARB-based
regimens reduced major cardiovascular events more than
did control regimens (10%, [4– 17]; figure 2). There were
no significant differences between regimens based on
ACE inhibitors, calcium antagonists, or diuretics or 
blockers, and CIs were narrow for the estimate for every
comparison (figure 3). 
Cardiovascular death
Compared with placebo, ACE-inhibitor-based regimens
reduced the risk of cardiovascular death (20% [11–29])
(figure 1). There was a trend towards fewer deaths with
calcium-antagonist-based regimens (22% [0–39]), but no
clear evidence of a reduction in risk with regimens
targeting low blood pressure goals (7% [–11 to 23]) or
between ARB-based regimens and control regimens (4%
[–8 to 15]; figure 2). Effects on cardiovascular mortality
did not differ significantly between regimens based 
on ACE inhibitors, calcium-antagonists, or diuretics or 
 blockers (figure 3). 
Total mortality
In trials comparing ACE-inhibitor-based regimens and
placebo, active treatment reduced the risk of death (12%
[4–19]; figure 1). There was no clear evidence of a
difference in this outcome in trials comparing calcium-
antagonist-based regimens and placebo or in those
comparing regimens targeting different blood pressure
goals (11% [–5 to 25] and 4% [–9 to 16], respectively).
Similarly, total mortality did not differ between ARB-
based regimens and control regimens (6% [–2 to 14];
figure 2) or between treatment regimens based on ACE
inhibitors, calcium-antagonists, or diuretics or  blockers
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Stroke12–15
Coronary heart
disease12–15
Heart failure13–15
4
4
3
–2/–1
–2/–1
–2/–1
0·79 (0·69–0·90) 0·46
0·96 (0·85–1·09) 0·43
0·84 (0·72–0·97) 0·26
396/8412
435/8412
302/5935
500/8379
450/8379
359/5919
Major cardiovascular
events12–15
Cardiovascular 
death12–15
Total mortality12–15
4
4
4
–2/–1
–2/–1
–2/–1
0·90 (0·83–0·96) 0·78
0·96 (0·85–1·08) 0·34
0·94 (0·86–1·02) 0·59
1135/8412
491/8412
887/8412
1268/8379
511/8379
943/8379
0·5 1·0
Relative risk
Favours ARB Favours control
2·0
Trials Events/participants
ARB          Control
Difference in BP*
(mean, mm Hg)
Relative risk
(95% Cl)
p
Figure 2: Comparisons of ARB-based regimens with control regimens 
*Overall mean blood pressure difference (systolic/diastolic) during follow-up in the ARB group compared with the control group, calculated by weighting the
difference observed in each contributing trial by the number of individuals in the trial. Negative values indicate lower mean follow-up blood pressure levels
in the ARB group than in controls. p values from 2 test for homogeneity.
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(figure 3). There was significant heterogeneity in trials that
were included in the comparison of regimens targeting
different blood pressure goals (p=0·09). Recalculation of
the estimate and its 95% CIs with a random effects model
made little difference (11% [–10 to 29]).
Blood pressure differences and risk reductions
For all seven randomised comparisons, the weighted
mean blood pressure differences between randomised
groups seemed to be directly associated with differences in
risks of stroke, coronary heart disease, major
cardiovascular events, cardiovascular death, and total
mortality (figure 4). By contrast, blood pressure
differences did not seem to be associated with risk of heart
failure. In our present analyses, we did not investigate the
separate association between blood pressure differences
and outcome in trials of individual drug classes.
Discussion
Our results show that treatment with any commonly-used
regimen reduces the risk of total major cardiovascular
events, and that larger reductions in blood pressure
produce larger reductions in risk. These results confirm
earlier analyses4 showing benefits of ACE-inhibitor-based
regimens across a wide range of hypertensive and non-
hypertensive patients at high risk of cardiovascular
disease, and of calcium-antagonist-based regimens in
hypertensive patients.
The results of this meta-analysis also indicate differences
between regimens based on different drugs in their effects
on cause-specific cardiovascular outcomes. Although some
of these differences seem to be largely explained by
differences in achieved blood pressure, others seem to be
independent of such differences. The results of previous
overviews4,9 and individual trials30,32–34 had raised this
possibility, but until the completion of the present
analyses, whether the findings were real was unknown. 
Our results show that regimens based on ACE
inhibitors or on diuretics or  blockers are much more
effective at preventing heart failure than are regimens
based on calcium antagonists. Since the current analyses
were restricted to cases of heart failure that resulted in
death or admission to hospital, minor side-effects of
calcium antagonists, such as peripheral oedema, are
unlikely to be wholly responsible for this finding. The
differences between these regimens are not easily
ARTICLES
1532 THE LANCET • Vol 362 • November 8, 2003 • www.thelancet.com
Stroke
ACEI vs D/BB32–35,44
CA vs D/BB18,25,32,35–40
ACEI vs CA30–32,35,41
5
9
5
+2/0
+1/0
+1/+1
1·09 (1·00–1·18)  0·13
0·93 (0·86–1·00)  0·67
1·12 (1·01–1·25)  0·20
984/20 195
999/31 031
701/12 562
1178/26 358
1358/37 418
622/12 541
Coronary heart disease
ACEI vs D/BB32–35,44
CA vs D/BB18,25,32,35–40
ACEI vs CA30–32,35,41
5
9
5
+2/0
+1/0
+1/+1
0·98 (0·91–1·05)  0·21
1·01 (0·94–1·08)  0·48
0·96 (0·88–1·04)  0·01
1172/20 195
1394/31 031
907/12 562
1658/26 358
1840/37 418
948/12 541
Heart failure
ACEI vs D/BB32,33,44
CA vs D/BB18,25,32,36–38,40
ACEI vs CA30–32,41
3
7
4
+2/0
+1/0
+1/+1
1·07 (0·96–1·19)  0·43
1·33 (1·21–1·47)  0·92
0·82 (0·73–0·92)  0·75
547/12 498
732/23 425
502/10 357
809/18 652
850/29 734
609/10 345 
Major cardiovascular events
ACEI vs D/BB29,32–35,44
CA vs D/BB18,25,32,35–40
ACEI vs CA30–32,41
6
9
5
+2/0
+1/0
+1/+1
1·02 (0·98–1·07)  0·31
1·04 (1·00,1·09)   0·92
0·97 (0·92–1·03)  0·22
2581/20 631
2998/31 031
1953/12 562
3450/26 799
3839/37 418
2011/12541 
Cardiovascular death
ACEI vs D/BB29,32–35,44
CA vs D/BB18,25,32,35–40
ACEI vs CA30–32,41
6
9
5
+2/0
+1/0
+1/+1
1·03 (0·95–1·11)  0·36
1·05 (0·97–1·13)  0·33
1·03 (0·94–1·13)  0·56)
1061/20 631
1237/31 031
870/12 562
1440/26 799
1584/37 418
840/12 541 
Total mortality
ACEI vs D/BB29,32–35,43
CA vs D/BB18,25,32,35–40
ACEI vs CA2629–32,35,41
6
9
6
+2/0
+1/0
+1/+1
0·5 1·0
Relative risk
Favours 1st
listed
Favours 2nd
listed
2·0
1·00 (0·95–1·05)  0·76
0·99 (0·95–1·04)  0·71
     1·04 (0·98–1·10)  0·68
2176/20 631
2527/31 031
1763/12 998
3067/26 799
3437/37 418
1683/12 758
Trials Events/participants
1st listed       2nd listed
Difference in BP*
(mean, mm Hg)
Relative risk
(95% Cl)
p
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accounted for by their comparative effects on blood
pressure and are broadly consistent with results of trials of
ACE inhibitors7 and calcium antagonists45,46 in patients
with heart failure. Our results also showed a greater effect
of ARB-based regimens than other control regimens on
the risk of heart failure, although this might, at least in
part, be related to the greater reduction in blood pressure. 
Unlike in earlier analyses,4 our results for coronary heart
disease showed no trend towards a lesser effect of calcium
antagonists compared with diuretics or  blockers, or
ACE inhibitors. Narrow CIs excluded all but a trivial
difference in risk, thereby confirming conclusions from
earlier reports,47,48 questioning the validity of claims of
large increases in coronary risk in hypertensive patients
treated with calcium antagonists. Our results showed no
clear difference in risk of coronary heart disease between
regimens based on ACE inhibitors and those based on
diuretics or  blockers, despite somewhat smaller blood
pressure reductions with ACE inhibitors than with
diuretics or  blockers. Conversely, we noted no clear
difference in risk of coronary heart
disease between ARB-based and
control regimens, despite greater blood
pressure reductions with ARBs.
For stroke, we observed a greater
effect of regimens based on calcium
antagonists compared with those based
on diuretics or  blockers, but the
result was of borderline significance.
We also noted a trend towards greater
reductions in stroke risk with regimens
based on calcium antagonists and
diuretics or -blockers than with
regimens based on ACE inhibitors. A
greater reduction in stroke risk was
noted with ARB-based regimens
compared with control regimens that
were less effective in reducing blood
pressure. For all these differences there
remains some uncertainty as to
whether they can be accounted for
entirely by differences in achieved
blood pressure levels. 
Although modest independent
effects of specific drug classes on stroke
or risk of coronary heart disease are not
precluded by our findings, the results
do suggest that blood pressure
lowering is a major component of the
benefit conferred by the regimens
investigated. Direct evidence is
provided by the regimens targeting
different blood pressure goals (with
various drug classes), which showed
larger reductions in stroke and total
major cardiovascular events from
regimens targeting lower blood
pressure goals. Indirect evidence is
provided by the association of
differences in blood pressure between
randomised groups with differences in
risks of stroke, coronary heart disease,
and the composite outcomes of total
major cardiovascular events and death
(figure 4). For heart failure, however,
blood pressure differences and the
relative risk of this outcome were not
clearly associated. This seemed to
result, at least in part, from the
divergent effects of calcium-antagonist-based regimens on
this outcome—an effect that seemed to be determined
mainly by factors other than reduction of blood pressure.
A similar observation has been made with regard to the
effect of the -adrenergic blocker, doxazosin, on the risk
of heart failure.16
Combination of data from multiple trials addressing the
same question reduces random errors and increases the
precision of estimates of treatment effects and differences.
Random errors in the estimates of blood pressure
differences would be especially small, since every
comparison is based on data from several thousand
individuals per treatment group. Systematic errors were
minimised by prespecifying the criteria for inclusion of
trials, the comparisons to be studied, and the outcomes to
be reported.4,11 Analyses were based on relative risk
estimates rather than hazard ratios, but this does not seem
to have substantially affected the findings: sensitivity
analyses based on hazard ratios, previously published by
contributing studies, identified no estimate of the pooled
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Figure 4: Associations of blood pressure differences between groups with risks of
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The circles are plotted at the point estimate of effect for the relative risk for every event type and the
mean follow-up blood pressure in the 1st listed group compared with the 2nd listed group. Vertical
lines are 95% CIs. CHD=coronary heart disease. CVD=cardiovascular event. CV death=
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pressure–lowering, from references 17, 24, 29–31. D) ARB vs control, from references 12–15. 
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 blocker from references 29, 32–35. 
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risk reduction that differed by more than one percent. The
analyses were not adjusted for differences in achieved
blood pressure or patients’ characteristics, such as disease
history or baseline blood pressure. Although a few
outcome data were missing from some studies, subsidiary
analyses suggest that this is unlikely to have had an
important effect on the findings. 
The analyses of heart failure reported here with data
from 22 of the 29 studies, did not differ substantially from
the findings of supplementary analyses including three
additional trials that provided heart failure data based on a
less restrictive definition than ours. Other supplementary
analyses showed that these missing data were unlikely to
have greatly affected estimates of treatment effects and
treatment differences for total major cardiovascular
events. Incomplete adherence to randomised treatments
will, however, have resulted in substantial and systematic
underestimation of both the effects of active treatments
compared with control, and the differences between
regimens based on different drug classes.4 In general,
about two-thirds of participants remained on randomised
treatment at the end of follow-up. Assuming uniform loss
of compliance over time, the treatment effect that would
have been seen with complete adherence would be about
20% greater than that noted.
Evidence of heterogeneity of outcome in contributing
trials was seen for two comparisons, those of ACE-
inhibitor-based regimens versus calcium-antagonist-based
regimens for coronary heart disease (p=0·01) and, of
regimens targeting different blood pressure goals for total
mortality (p=0·09). Heterogeneity in the comparison of
ACE-inhibitor-based regimens versus calcium-antagonist-
based regimens was mainly due to one trial,30 and neither
exclusion of that trial from the fixed-effect model nor the
use of a random-effect model in either comparison altered
the conclusions. Stratification of the analyses by method
of treatment allocation (double-blind or open) identified
one comparison for which there was some evidence of
heterogeneity (p=0·04); there was a trend towards a lower
risk of coronary heart disease with diuretic or -blocker-
based regimens than with calcium-antagonist-based
regimens in open trials35,39 but not in double-blind
studies18,25,29,31,36–38 However, exclusion of the open studies
from the analysis did not alter the conclusions. 
Stratification of drug regimens into major subgroups
identified no significant heterogeneity. In the comparisons
of calcium-antagonist-based regimens, there was no signi-
ficant evidence of heterogeneity for any outcome between
trials that used dihydropyridine agents and those that 
used non-dihydropyridine agents. In the comparisons of
diuretic or -blocker-based regimens with other regimens,
there was no evidence of heterogeneity for any outcome
between trials that used diuretic alone, those that used 
 blockers alone, or those that allowed the use of either as
initial treatment. However, investigators in one large trial32
reported reduced risks of cardiovascular events with a
regimen based on the diuretic chlorthalidone, compared
with that based on an ACE inhibitor.
Our results provide answers to questions about the
effects of several commonly-used blood-pressure-lowering
regimens for patients with high blood pressure or those
otherwise at risk of major cardiovascular events. The
findings are consistent with results of most of the large
contributing trials, with small differences that might
indicate the increased precision of our analyses, slight
differences in treatment regimens, or differing ethnic
backgrounds of participants. With respect to ethnic
background, results in one large trial32 showed a smaller
reduction of total major cardiovascular events with ACE-
inhibitors than with diuretic; this seems to be due, at least
in part, to the large proportion of African-American
patients in the study and the much smaller reduction in
blood pressure achieved with ACE inhibitor in that
subgroup. However, although several questions are
resolved by these analyses, others remain unanswered.
For example, the findings of several individual studies13,17,29
indicate that some regimens might be of greater or lesser
benefit for patients with established diseases, such as
diabetes or nephropathy, or in outcomes that were not
included in the current overviews, such as new-onset
diabetes or renal failure. 
We have sufficient data to do further subsidiary
analyses11 that will address these and related questions.
Planned analyses of the associations between blood
pressure differences and risk reductions in trials of every
drug class should also make clear the contribution of blood
pressure lowering versus other drug-specific mechanisms
to treatment outcomes. Until such findings are known, our
results, assessed in the context of other relevant data49,50
and treatment guidelines,51,52 should enhance the ability of
clinicians and health policy makers to make evidence-
based decisions about the use of the different blood-
pressure-lowering regimens currently available.
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